Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved progression-free survival (PFS) and time-to-progression in patients with locally advanced hepatocellular carcinoma (HCC) when compared to sorafenib alone.
Pfizer gains FDA approval for rare childhood leukaemia drug – Pharmaceutical Technology
Bosutinib has been approved for adult use for over a decade, but the FDA has given the green light for use in children older than
September 28, 2023